肠道菌群与神经性疾病的研究进展
Research Progress of Intestinal Flora and Neurological Diseases
DOI: 10.12677/ACM.2022.121093, PDF,  被引量   
作者: 邹嫄媛*, 徐君铭#：昆明医科大学生物医学工程研究中心，云南省干细胞和再生医学重点实验室，云南 昆明；郑钦日：马来西亚博特拉大学生物科学研究所益生菌与治疗研究实验室，沙登，雪兰莪，马来西亚
关键词: 肠道菌群；神经退行性疾病；益生菌；Intestinal Flora； Neurodegenerative Diseases； Probiotics
摘要: 肠道菌群是驻留在肠粘膜中的多种微生物种群，人类胃肠道中定植着数万亿的微生物(主要是细菌，还有古细菌，病毒和原生动物)，其数量是人体之最。肠道内大量的肠道菌群构成了肠道微生态循环系统，在人体营养吸收、代谢改善、屏障保护等各种生理活动中发挥着重要作用，此外肠道菌群失调将会对宿主各个系统产生不同程度的影响。最近研究发现肠道菌群与退行性神经疾病之间通过“脑肠轴”相互影响，肠道菌群的失调会影响增加退行性疾病的患病风险，同样退行性疾病的发生也会导致肠道菌群的改变。本文综述肠道菌群与神经性疾病的研究进展，为神经性疾病的预防及治疗提供新的思路。
Abstract: The intestinal flora is a population of multiple microorganisms that reside in the intestinal mucosa. The intestine is home to trillions of microorganisms (mainly bacteria, but also archaea, viruses, and protozoa), the number of which is the largest in the human body. A large number of intestinal flora constitute the intestinal microecological circulation system, which plays an important role in various physiological activities such as human nutrition absorption, metabolism improvement, barrier protection, etc. In addition, the imbalance of intestinal flora will have varying degrees of impact on various host systems. Recent studies have found that the intestinal flora and degenerative neurological diseases affect each other through the “brain gut axis”. The imbalance of the intestinal flora will increase the risk of degenerative diseases, and the occurrence of the same degenerative diseases will also lead to changes in the gut microbiota. This article reviews the research progress of intestinal flora and neurological diseases, which is expected to provide new ideas for disease prevention and treatment.
文章引用：邹嫄媛, 郑钦日, 徐君铭. 肠道菌群与神经性疾病的研究进展[J]. 临床医学进展, 2022, 12(1): 627-632. https://doi.org/10.12677/ACM.2022.121093

参考文献

[1] Tan, F.H.P., Liu, G., Lau, S.A., et al. (2020) Lactobacillus Probiotics Improved the Gut Microbiota Profile of a Drosophila Melanogaster Alzheimer’s Disease Model and Alleviated Neurodegeneration in the Eye. Beneficial Microbes, 11, 79-89. [Google Scholar] [CrossRef] 
[2] Chang, C.H., Lin, C.H. and Lane, H.Y. (2020) D-glutamate and Gut Microbiota in Alzheimer’s Disease. International Journal of Molecular Sciences, 21, 2676. [Google Scholar] [CrossRef] [PubMed]
[3] Medina-Rodriguez, E.M., Madorma, D., O’Connor, G., et al. (2020) Identification of a Signaling Mechanism by Which the Microbiome Regulates Th17 Cell-Mediated Depressive-Like Behaviors in Mice. American Journal of Psychiatry, 177, 974-990. [Google Scholar] [CrossRef] [PubMed]
[4] Kesika, P., Suganthy, N., Sivamaruthi, B.S., et al. (2021) Role of Gut-Brain Axis, Gut Microbial Composition, and Probiotic Intervention in Alzheimer’s Disease. Life Sciences, 264, Article ID: 118627. [Google Scholar] [CrossRef] [PubMed]
[5] Sun, Z.Z., Li, X.Y., Wang, S., et al. (2020) Bidirectional Interactions between Curcumin and Gut Microbiota in Transgenic Mice with Alzheimer’s Disease. Applied Microbiology and Biotechnology, 104, 3507-3515. [Google Scholar] [CrossRef] [PubMed]
[6] Hemmings, S.M.J., Malan-Müller, S., van den Heuvel, L.L., et al. (2017) The Microbiome in Posttraumatic Stress Disorder and Trauma-Exposed Controls: An Exploratory Study. Psychosomatic Medicine, 79, 936-946. [Google Scholar] [CrossRef] 
[7] Bersani, F.S., Mellon, S.H., Lindqvist, D., et al. (2020) Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, the Gut Microbiome, and Mitochondrial Dysfunction. Military Medicine, 185, 311-318. [Google Scholar] [CrossRef] [PubMed]
[8] Gareau, M.G., Sherman, P.M. and Walker, W.A. (2010) Probiotics and the Gut Microbiota in Intestinal Health and Disease. Nature Reviews Gastroenterology & Hepatology, 7, 503-514. [Google Scholar] [CrossRef] [PubMed]
[9] Meyyappan, A.C., Forth, E., Wallace, C.J.K., et al. (2020) Effect of Fecal Microbiota Transplant on Symptoms of Psychiatric Disorders: A Systematic Review. BMC Psychiatry, 20, Article No. 299. [Google Scholar] [CrossRef] [PubMed]
[10] Dodiya, H.B., Frith, M., Sidebottom, A., et al. (2020) Synergistic Depletion of Gut Microbial Consortia, But Not Individual Antibiotics, Reduces Amyloidosis in APPPS1-21 Alzheimer’s Transgenic Mice. Scientific Reports, 10, Article No. 8183. [Google Scholar] [CrossRef] [PubMed]
[11] Domingues, R., et al. (2021) Therapies for Alzheimer’s Disease: A Metabolic Perspective. Molecular Genetics and Metabolism, 132, 162-172. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, F., Chen, H., Zhang, R., et al. (2020) 5-Fluorouracil Induced Dysregulation of the Microbiome-Gut-Brain Axis Manifesting as Depressive like Behaviors in Rats. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1866, Article ID: 165884. [Google Scholar] [CrossRef] [PubMed]
[13] Peñalver, B.B., Maki, P.M., Dowty, S.M., et al. (2020) Precision Medicine in Perinatal Depression in Light of the Human Microbiome. Psychopharmacology (Berl), 237, 915-941. [Google Scholar] [CrossRef] [PubMed]
[14] Li, S., Hua, D., Wang, Q., et al. (2020) The Role of Bacteria and Its Derived Metabolites in Chronic Pain and Depression: Recent Findings and Research Progress. International Journal of Neuropsychopharmacology, 23, 26-41. [Google Scholar] [CrossRef] [PubMed]
[15] Kalin, N.H. (2021) Trauma, Resilience, Anxiety Disorders, and PTSD. American Journal of Psychiatry, 178, 103-105. [Google Scholar] [CrossRef] [PubMed]
[16] Leclercq, S., Forsythe, P. and Bienenstock, J. (2016) Posttraumatic Stress Disorder: Does the Gut Microbiome Hold the Key? The Canadian Journal of Psychiatry, 61, 204-213. [Google Scholar] [CrossRef] [PubMed]
[17] Cryan, J.F. (2016) Stress and the Microbiota-Gut-Brain Axis: An Evolving Concept in Psychiatry. The Canadian Journal of Psychiatry, 61, 201-203. [Google Scholar] [CrossRef] [PubMed]
[18] Gautam, A., Kumar, R., Chakraborty, N., et al. (2018) Altered Fecal Microbiota Composition in All Male Aggressor-Exposed Rodent Model Simulating Features of Post-Traumatic Stress Disorder. Journal of Neuroscience Research, 96, 1311-1323. [Google Scholar] [CrossRef] [PubMed]
[19] Martínez-Larrosa, J., Matute-Blanch, C., Montalban, X., et al. (2020) Modelling Multiple Sclerosis Using Induced Pluripotent Stem Cells. Journal of Neuroimmunology, 349, Article ID: 577425. [Google Scholar] [CrossRef] [PubMed]
[20] Schepici, G., Silvestro, S., Bramanti, P., et al. (2019) The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials. Cell Transplantation, 28, 1507-1527. [Google Scholar] [CrossRef] [PubMed]
[21] Takewaki, D., Suda, W., Sato, W., et al. (2020) Alterations of the Gut Ecological and Functional Microenvironment in Different Stages of Multiple Sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 117, 22402-22412. [Google Scholar] [CrossRef] [PubMed]
[22] Ahmed, N., Ghannoum, M., Gallogly, M., et al. (2020) Influence of Gut Microbiome on Multiple Myeloma: Friend or Foe? Journal for ImmunoTherapy of Cancer, 8, e000576. [Google Scholar] [CrossRef] [PubMed]
[23] Vuotto, C., Battistini, L., Caltagirone, C., et al. (2020) Gut Microbiota and Disorders of the Central Nervous System. Neuroscientist, 26, 487-502. [Google Scholar] [CrossRef] [PubMed]
[24] Jiang, C.M., Li, G.N., Huang, P.R., et al. (2017) The Gut Microbiota and Alzheimer’s Disease. Journal of Alzheimer’s Disease, 58, 1-15. [Google Scholar] [CrossRef] 
[25] Wang, X., Sun, G., Feng, T., et al. (2019) Sodium Oligomannate Therapeutically Remodels Gut Microbiota and Suppresses Gut Bacterial Amino Acids-Shaped Neuroinflammation to Inhibit Alzheimer’s Disease Progression. Cell Research, 29, 787-803. [Google Scholar] [CrossRef] [PubMed]
[26] 薛刘军, 欧洲, 王丽君, 等. 粪菌移植替代多巴胺能药物治疗帕金森病案例分析[J]. 临床神经病学杂志, 2019, 32(5): 329-332.
[27] Blacher, E., Bashiardes, S., Shapiro, H., et al. (2019) Potential Roles of Gut Microbiome and Metabolites in Modulating ALS in Mice. Nature, 572, 474-480. [Google Scholar] [CrossRef] [PubMed]
[28] Borody, T., Leis, S., Campbell, J., et al. (2011) Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis (MS). American Journal of Gastroenterology, 106, S352. [Google Scholar] [CrossRef] 

为你推荐